Loading...
01/11 03:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Cash and Cash Equivalents As of September 30, 2025, the cash and cash equivalents and restricted cash balance was $15.8 million, compared to $24.9 million as of September 30, 2024, representing a decrease. The decrease is attributed to the company's operating expenses and investments in drug development.
Net Proceeds from Public Offering On October 31, 2025, the company completed a public offering resulting in net proceeds of approximately $23.4 million. This was used to support the company's operations and drug development programs.
Research and Development Costs Increased to $15.6 million in fiscal 2025 from $12.8 million in the prior year, representing a year-over-year increase. The increase is due to expenses related to the Phase IIb QUALITY clinical study for enobosarm.
Selling, General and Administrative Expenses Decreased to $19.9 million in fiscal 2025 from $24.6 million in the prior year, representing a year-over-year decrease. The decrease is primarily due to reduced share-based compensation expenses.
Net Loss from Continuing Operations For fiscal 2025, the net loss was $15.7 million or $1.07 per diluted common share, compared to a net loss of $35.3 million or $2.61 per diluted common share in the prior year. The improvement is due to gains from the sale of assets and reduced operating expenses.
Net Loss from Discontinued Operations For fiscal 2025, the net loss was $7 million or $0.48 per diluted common share, compared to $2.5 million or $0.19 per diluted common share in the prior year. The increase is due to the loss on the sale of the FC2 Female Condom business and reduced gross profit.
Gain on Sale of ENTADFI Assets Recognized a gain of $10.8 million in fiscal 2025, compared to $1.2 million in the prior year. The increase is due to nonrefundable consideration received related to promissory notes.
Cash Used in Operating Activities Used $30 million for operating activities in fiscal 2025, compared to $21.7 million in the prior year, representing an increase. The increase is due to higher operating expenses and investments in drug development.
Cash Generated from Investing Activities Generated $25.1 million in fiscal 2025, compared to $0.1 million in the prior year. The increase is due to proceeds from the sale of the FC2 Female Condom business and ENTADFI assets.
Enobosarm: An oral selective androgen receptor modulator (SARM) developed to enhance weight reduction by GLP-1 receptor agonist drugs, focusing on fat loss while preserving lean mass. Phase IIb clinical trial results showed 100% lean mass preservation and 12% greater fat loss compared to placebo. It also demonstrated improved physical function and reduced weight regain after discontinuation of semaglutide.
Sabizabulin: A microtubule disruptor being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation and slow the progression of atherosclerotic cardiovascular disease.
Obesity Drug Market: Targeting older patients with obesity, especially those with a BMI ≥ 35 and aged ≥ 65. The company plans to address the weight loss plateau observed in GLP-1 receptor agonist treatments with a combination therapy of enobosarm and GLP-1 receptor agonists.
Financial Position: Cash and cash equivalents as of September 30, 2025, were $15.8 million. A public offering in October 2025 raised $23.4 million. The company plans to use these funds to support the Phase IIb PLATEAU clinical study.
Sale of FC2 Female Condom Business: The business was sold for $18 million, with net proceeds of $16.5 million. This sale represents a strategic shift to focus exclusively on drug development.
Strategic Focus: Shifted focus exclusively to drug development by selling the FC2 Female Condom business and reallocating resources to the development of enobosarm and sabizabulin.
Regulatory Challenges: The regulatory landscape for muscle preservation drugs in obesity treatment is evolving, and Veru must navigate FDA guidance for enobosarm's approval. This includes meeting specific efficacy endpoints, such as incremental weight loss or clinically significant benefits, which could delay or complicate the approval process.
Financial Constraints: Veru reported a net loss of $15.7 million from continuing operations and $7 million from discontinued operations in fiscal 2025. The company is not profitable, has negative cash flow from operations, and will require additional capital to fund its drug development programs, posing a risk to its financial stability.
Market Competition: The obesity drug market is highly competitive, with major players like Eli Lilly, Versanis, Scholar Rock, and Regeneron also developing treatments. This competitive pressure could impact Veru's market share and revenue potential.
Supply Chain and Operational Risks: The company has shifted its focus entirely to drug development after selling its FC2 Female Condom business. This strategic shift may introduce operational risks as Veru transitions to a single focus on biopharmaceuticals.
Clinical Development Risks: The success of Veru's enobosarm and sabizabulin programs depends on positive clinical trial outcomes. Any setbacks in these trials could adversely affect the company's strategic objectives and financial performance.
Economic Uncertainty: The company’s reliance on public offerings and external funding makes it vulnerable to economic fluctuations, which could impact its ability to raise necessary capital.
Enobosarm Clinical Development Plan: The FDA has provided two regulatory pathways for enobosarm in combination with GLP-1 receptor agonists: (1) achieving at least a 5% placebo-corrected weight loss difference at 52 weeks of maintenance treatment, or (2) demonstrating clinically significant benefits such as preservation of physical function even with less than 5% incremental weight loss. The next study, Phase IIb PLATEAU clinical trial, will target patients with obesity (BMI ≥ 35) and aged ≥ 65 to assess enobosarm's ability to break through weight loss plateaus. The trial will evaluate total body weight change, physical function, and safety over 72 weeks, with an interim analysis at 36 weeks. The study is expected to begin in Q1 2026, with interim results anticipated in Q1 2027.
Phase IIb QUALITY Clinical Trial Results: The trial demonstrated that enobosarm 3 mg combined with semaglutide preserved 100% lean mass and achieved 12% greater fat loss compared to semaglutide alone over 16 weeks. Enobosarm also reduced the proportion of patients experiencing physical function decline by 59.8%. During the maintenance phase, enobosarm monotherapy significantly reduced weight regain by 46% and preserved lean mass. The drug showed a positive safety profile with no significant adverse events.
Market Opportunity and Strategic Focus: The company plans to target the growing population of patients experiencing weight loss plateaus with GLP-1 receptor agonists. Enobosarm is positioned as a complementary therapy to address this unmet need, potentially reducing the need for bariatric surgery and improving outcomes for patients with obesity.
Financial Position and Funding: As of September 30, 2025, the company had $15.8 million in cash and cash equivalents, with an additional $23.4 million raised through a public offering in October 2025. This funding is expected to support operations through the interim analysis of the Phase IIb PLATEAU clinical trial.
The selected topic was not discussed during the call.
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
Despite some positive aspects like reduced net loss and exploration of partnerships, the overall financial health shows increased research costs and reduced cash reserves. The Q&A reveals uncertainty in funding and study designs, contributing to a negative sentiment. The lack of concrete guidance and strategic clarity further dampens investor confidence.
The earnings call reveals a decrease in cash reserves, increased R&D costs, and a significant net loss from operations, which are concerning. The Q&A section highlights uncertainties around cash runway and funding for Phase 3 trials, with management avoiding direct answers. These factors suggest potential financial strain and uncertainties, likely resulting in a negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
